sitagliptin glp 1 agonist Frontiers Frontiers | GLP−1 receptor agonists
Description
Once-daily subcutaneous (s.c.) injections of the potent NMDA receptor antagonist MK-801 in diet-induced obese (DIO) mice led to a dose-dependent decrease in food intake and body weight (Extended Data Fig
"Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial." JAMA psychiatry 82.4 (2025): 395-405
Bottom line, they work, Matias Muchnick, co-founder and CEO of NotCo, explained in a social media post
Strain WD, Frenkel O, James MA, Leiter LA, Rasmussen S, Rothwell PM, Sejersten Ripa M, Truelsen TC, Husain M
This disconnect is specific to patients taking GLP-1 medications, Fanty says
